Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Regeneron Failure Could Hurt Rivals More

Executive Summary

A Friday morning clinical trial result at Regeneron had implications across a large number of companies marketing and developing ant-VEGF and anti-PDGF drugs including Ophthotech, Allergan, Roche and Novartis.

Advertisement

Related Content

Fovista AMD Failure Puts Eylea In The Clear, Blurs Anti-PDGF Prospects
Stockwatch: The TIGER That Came To Lilly
STOCKWATCH: Reasons to be tearful

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register